RVL Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017	2016
Net Income	-51.69	-64.92	-79.59	-270.9	-109.68	-41.14	-41.82
Depreciation & Amortization	0.38	8.18	21.03	57.02	81.57	46.45	23.59
Share-Based Compensation	4.07	7.59	4.93	4.93	1.97	0	1.16
Other Operating Activities	9.44	-5.58	71.23	242.52	63.7	52.53	-27.71
Operating Cash Flow	-37.81	-54.73	17.59	33.57	37.56	57.84	-44.79
Operating Cash Flow Growth	-	-	-47.60%	-10.63%	-35.06%	-	-
Capital Expenditures	0.13	-1.69	-3.08	-4.02	-4.13	-6.9	-13.93
Acquisitions	0	118.15	0	0	0	-12.5	-437.53
Other Investing Activities	-	-	-	-	-	-	-2
Investing Cash Flow	0.13	116.45	-3.08	-4.02	-4.13	-19.4	-453.46
Dividends Paid	0	0	0	0	0	0	-23.31
Share Issuance / Repurchase	23.83	32.65	54.56	-2.79	58.08	0	0
Debt Issued / Paid	18.1	-167.19	-50.13	-1.9	-54.48	-11.37	338.24
Other Financing Activities	-0.14	-0.78	-0.75	-	-0	-11.94	105.59
Financing Cash Flow	41.78	-135.33	3.68	-4.69	3.6	-23.31	420.52
Exchange Rate Effect	0	0	0	0.18	-0.94	0.06	-0.32
Net Cash Flow	4.1	-73.61	18.19	24.86	37.03	15.13	-77.74
Free Cash Flow	-37.68	-56.42	14.51	29.55	33.42	50.94	-58.72
Free Cash Flow Growth	-	-	-50.91%	-11.60%	-34.39%	-	-
Free Cash Flow Margin	-75.79%	-322.40%	52.25%	12.31%	12.67%	20.73%	-26.88%
Free Cash Flow Per Share	-0.42	-0.84	0.24	0.56	0.74	1.19	-58.71

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).